DALLAS, May 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that several of the Company's officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions on May 10, 2024 and May 15, 2024. The Company continues to make significant strides toward commercializing ...

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the "AGM"). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company. The voting results are detailed below. Six directors were elected ...

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the "AGM"). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company. The voting results are detailed below. Six directors were elected ...

财务数据和关键指标变化 - 第一季度研发收入同比增长24.6%至6.3百万美元 [16] - 毛利率从去年同期的42.9%提升至46.6% [16] - 净亏损从去年同期的3.6百万美元收窄至3.2百万美元 [17] - 3月31日现金及现金等价物为10.2百万美元,较年末增加5.4百万美元 [18] 各条业务线数据和关键指标变化 - 公司正在美国多个烧伤中心和急诊科为烧伤适应症开展240例患者的关键性临床试验,目前已完成20%的入组 [9] - 正在美国和英国推进糖尿病足溃疡的培训和验证性临床试验,已入组470例患者 [9] 各个市场数据和关键指标变化 - 在英国获得UKCA认证,已在3家医院部署6台DeepView AI-Burn设备,预计下半年开始商业交易 [8][25] - 公司正与海湾合作委员会国家进行互动,探索在该地区进行试验和测试 [58] 公司战略和发展方向及行业竞争 - 公司正从临床环境向商业化转型,2024年及以后的业务重点已明确 [8] - 公司成立知识产权子公司Spectral IP,由知名知识产权专家Erich Spangenberg担任CEO,将寻求资产收购和子公司独立上市 [13][14] - 公司与BARDA的合作关系良好,BARDA为公司提供临床试验设计等方面的建议 [38][39][40] 管理层对经营环境和未来前景的评论 - 第一季度烧伤发生率有所下降,但预计第二季度和夏季会有所上升 [26][27] - 公司维持2024年约28百万美元的收入指引,较2023年增长55% [19] - 公司认为烧伤适应症可能优先于糖尿病足溃疡获得FDA批准 [32][33] 问答环节重要的提问和回答 问题1 **Unidentified Analyst 提问** 询问公司在英国的初始部署情况,以及医生的反馈 [23][24] **Peter Carlson 回答** 医生对该设备反馈积极,认为设备易于使用,可以提高诊断的一致性和质量 [25] 问题2 **Ramakanth Swayampakula 提问** 询问公司在糖尿病足溃疡适应症的临床试验进展和数据情况 [31][32] **Peter Carlson 回答** 公司有足够的数据准备英国提交,正在完成美国的验证性试验,预计今年完成 [32][33][34][35] 问题3 **John Vandermosten 提问** 询问公司AI系统的诊断原理和与医生诊断的关系 [42][43][44][45][46][47][48][49] **Peter Carlson 回答** 公司的AI系统是基于封闭数据库的算法,不存在无限迭代的风险,监管部门也更关注了解系统的工作原理 [46][47][48][49]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: SPECTRALAI, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 85-3987148 (State or other jurisdiction of (I.R.S. Em ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup New ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the company received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center (TMAC) for their UKCA Mark Attainment. "Spectral AI is honored to be recognized as an upcoming leader in the Texas Manufacturing space," ...

公司业绩 - Spectral AI公司将于2024年5月7日发布截至2024年3月31日的第一季度财务业绩[1] 公司背景 - Spectral AI公司是一家总部位于达拉斯的预测性人工智能公司，专注于医疗诊断，特别是针对烧伤和糖尿病足溃疡患者的更快、更准确的治疗决策[2] - 公司的DeepView®系统是一种预测性诊断设备，可以在治疗或其他医疗干预之前为临床医生提供对伤口愈合潜力的客观和即时评估[2] 前瞻性声明 - 公司的前瞻性声明包括关于公司战略、计划、目标、举措和财务展望的内容，提醒投资者谨慎对待这些前瞻性声明[3] 风险提示 - 投资者应仔细考虑公司在SEC提交的文件中描述的风险因素和其他风险和不确定性，以避免过度依赖前瞻性声明[5]

公司业绩 - Spectral AI公司将于2024年5月7日发布截至2024年3月31日的第一季度财务业绩[1] 公司定位 - Spectral AI公司专注于医疗诊断领域，致力于为伤口护理提供更快速、更准确的治疗决策[2] - 公司推出的DeepView®系统是一种预测性诊断设备，可以在治疗或其他医疗干预之前为临床医生提供伤口愈合潜力的客观和即时评估[2] 公司前瞻性陈述 - 公司的前瞻性陈述涉及战略、计划、目标、倡议和财务展望等方面[3] - 前瞻性陈述并非对未来业绩、状况或结果的保证，可能受到许多已知和未知的风险、不确定性、假设和其他重要因素的影响[4]